相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
D. Handolias et al.
BRITISH JOURNAL OF CANCER (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
Lucia Jilaveanu et al.
CLINICAL CANCER RESEARCH (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E
Florian A. Karreth et al.
MOLECULAR CELL (2009)
“Tumor immunology meets oncology IV”, 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany
Juergen Bukur et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Major response to imatinib mesylate in KIT-mutated melanoma
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells
Elisa Sala et al.
MOLECULAR CANCER RESEARCH (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
Jose Lutzky et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Improving melanoma classification by integrating genetic and morphologic features
Amaya Viros et al.
PLOS MEDICINE (2008)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma
Molly Yancovitz et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen et al.
BRITISH JOURNAL OF CANCER (2006)
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
KSM Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2006)
BAY 43-9006 inhibition of oncogenic RET mutants
F Carlomagno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models
MP Hoeflich et al.
CANCER RESEARCH (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mutant V599EB-RAF regulates growth and vascular development of malignant melanoma tumors
A Sharma et al.
CANCER RESEARCH (2005)
B-RAF is a therapeutic target in melanoma
M Karasarides et al.
ONCOGENE (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
